EL7.AI
StocksMedium•18 November 2026•
3 min read

Unable to Verify IceCure’s 83% U.S. Sales Growth Over Nine Months

Key Facts

1IceCure Medical shares closed at $0.8301 on November 17, 2026.
2The company’s revenue rose about 45% to $1.8 million in the first half of 2026, compared with $1.3 million in the corresponding period.
3Gross profit was $548,000 in the first half of 2026, compared with $349,000 in the first half of 2025.
4Cash and cash equivalents totaled about $12.0 million on June 30, 2026, compared with $8.9 million on December 31, 2025.
5The company scheduled its third-quarter results conference for November 18, 2026, at 10:00 a.m. Eastern Time.

Available data show that the company’s shares, listed under the ticker ICCM, closed at $0.8301 on November 17, 2026. That was the day before the date the company set for its third-quarter results conference. According to the investor relations calendar, the conference was scheduled for November 18 at 10:00 a.m. Eastern Time. This places the stock’s movement in the context of investors awaiting the period’s results, while no verified figures for those results are available here.

Previously published first-half results provide a verified indication of the company’s performance before the more recent period. Revenue rose about 45% to $1.8 million in the six months ended June 30, 2026, compared with $1.3 million in the same period of 2025. IceCure attributed the growth to increased sales of systems and disposable probes. Gross profit rose to $548,000 from $349,000 in the first half of the previous year. These figures show year-over-year growth in revenue and gross profit during that period, without establishing the trend for the subsequent nine months.

The company said its installed base of active ProSense commercial systems in the United States grew 70% through June 2026, after the system received marketing authorization from the Food and Drug Administration in October 2025. This metric relates to the installed base of active systems, not the number of states covered by sales or the rate of revenue growth. Commenting on the first-half results, Chief Executive Eyal Shamir said commercial adoption is generating additional clinical evidence. He added that clinical activity in turn supports commercial use, physician confidence and future reimbursement opportunities. Shamir linked clinical use with commercial expansion, saying each supports the other.

On liquidity, cash and cash equivalents totaled about $12.0 million on June 30, 2026, compared with $8.9 million on December 31, 2025. The comparison shows an increase in the balance between the two dates, without providing a breakdown of spending or liquidity in the third quarter. On reimbursement, the company said in October that the American Medical Association had not approved its request to move to a permanent Category I CPT code. It indicated it could resubmit the application in June 2027, while the temporary Category III code remained in effect. The company said the temporary code allows facilities to receive about $4,000 in facility fees for a ProSense procedure under the existing reimbursement framework.

The company had set its third-quarter results conference for November 18, 2026, at 10:00 a.m. Eastern Time. The conference would provide an opportunity to present results for the period ended September 30, the period covered by the headline of the statement cited in the available draft. First-half results, including 45% revenue growth, therefore remain the latest detailed financial metrics in the available evidence. The stock’s close at $0.8301 on November 17 also remains the latest verified price reading in the information provided.

Open on chart